Stock Track | Elanco Animal Health Soars 6.29% in Pre-market as Q2 Earnings Beat and Annual Guidance Raised

Stock Track

Aug 05

Elanco Animal Health Inc (ELAN) surged 6.29% in pre-market trading on Wednesday, as investors cheered second-quarter results that handily beat Wall Street estimates and an upward revision to the company's full-year outlook.

The animal-health company reported adjusted earnings per share of $0.34 for the quarter, well above the $0.27 consensus estimate. Revenue climbed 10% year-over-year to $1.37 billion, also exceeding the $1.31 billion analysts had forecast. The strong performance was driven by robust demand in the U.S. Pet Health segment, with new products Zenrelia and Credelio Quattro leading the growth.

Elanco raised its fiscal 2026 revenue guidance to a range of $5.09 billion to $5.14 billion, up from its prior view of $5.01 billion to $5.09 billion, and lifted its adjusted EPS forecast to $1.10–$1.16, compared with the previous $1.03–$1.09. Both ranges topped analysts' expectations, reinforcing confidence in the company's innovation pipeline and pricing power.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1187654167"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1187654167\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1187654167?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-05 19:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1187654167","market":"sg","top_or_hot":-1,"title":"Stock Track | Elanco Animal Health Soars 6.29% in Pre-market as Q2 Earnings Beat and Annual Guidance Raised","media":"Stock Track","content":"<p>Elanco Animal Health Inc (ELAN) surged 6.29% in pre-market trading on Wednesday, as investors cheered second-quarter results that handily beat Wall Street estimates and an upward revision to the company's full-year outlook.</p><p>The animal-health company reported adjusted earnings per share of $0.34 for the quarter, well above the $0.27 consensus estimate. Revenue climbed 10% year-over-year to $1.37 billion, also exceeding the $1.31 billion analysts had forecast. The strong performance was driven by robust demand in the U.S. Pet Health segment, with new products Zenrelia and Credelio Quattro leading the growth.</p><p>Elanco raised its fiscal 2026 revenue guidance to a range of $5.09 billion to $5.14 billion, up from its prior view of $5.01 billion to $5.09 billion, and lifted its adjusted EPS forecast to $1.10–$1.16, compared with the previous $1.03–$1.09. Both ranges topped analysts' expectations, reinforcing confidence in the company's innovation pipeline and pricing power.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Elanco Animal Health Soars 6.29% in Pre-market as Q2 Earnings Beat and Annual Guidance Raised</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Elanco Animal Health Soars 6.29% in Pre-market as Q2 Earnings Beat and Annual Guidance Raised\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-08-05 19:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Elanco Animal Health Inc (ELAN) surged 6.29% in pre-market trading on Wednesday, as investors cheered second-quarter results that handily beat Wall Street estimates and an upward revision to the company's full-year outlook.</p><p>The animal-health company reported adjusted earnings per share of $0.34 for the quarter, well above the $0.27 consensus estimate. Revenue climbed 10% year-over-year to $1.37 billion, also exceeding the $1.31 billion analysts had forecast. The strong performance was driven by robust demand in the U.S. Pet Health segment, with new products Zenrelia and Credelio Quattro leading the growth.</p><p>Elanco raised its fiscal 2026 revenue guidance to a range of $5.09 billion to $5.14 billion, up from its prior view of $5.01 billion to $5.09 billion, and lifted its adjusted EPS forecast to $1.10–$1.16, compared with the previous $1.03–$1.09. Both ranges topped analysts' expectations, reinforcing confidence in the company's innovation pipeline and pricing power.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ELAN","symbol_name":"Elanco Animal Health Inc","start_time":0,"source_url":"","article_id":"1187654167","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1187654167","pubTimestamp":1785928475,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Elanco Animal Health Inc (ELAN) surged 6.29% in pre-market trading on Wednesday, as investors cheered second-quarter results that handily beat Wall Street estimates and an upward revision to the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ELAN":"Elanco Animal Health Inc"},"translate_title":"股票跟踪 | Elanco Animal Health 第二季度盈利超出预期并上调年度指引，盘前股价飙升 6.29%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ELAN":1},"content_text":"Elanco Animal Health Inc (ELAN) surged 6.29% in pre-market trading on Wednesday, as investors cheered second-quarter results that handily beat Wall Street estimates and an upward revision to the company's full-year outlook.The animal-health company reported adjusted earnings per share of $0.34 for the quarter, well above the $0.27 consensus estimate. Revenue climbed 10% year-over-year to $1.37 billion, also exceeding the $1.31 billion analysts had forecast. The strong performance was driven by robust demand in the U.S. Pet Health segment, with new products Zenrelia and Credelio Quattro leading the growth.Elanco raised its fiscal 2026 revenue guidance to a range of $5.09 billion to $5.14 billion, up from its prior view of $5.01 billion to $5.09 billion, and lifted its adjusted EPS forecast to $1.10–$1.16, compared with the previous $1.03–$1.09. Both ranges topped analysts' expectations, reinforcing confidence in the company's innovation pipeline and pricing power.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}